Abarelix API Manufacturers
compare suppliers & get competitive offers
Filters
Reset
Selected filters:
Type
Production region
Qualifications
To view suppliers for this material, you need to be logged in first.
This is because of international laws regarding narcotic materials. Furthermore, the contents of this page are only accessible if you are professionaly active in the pharmaceutical industry. In case you are, it is possible to register on our platform, and after your account is approved by our team you will be able to view suppliers and send your request.
Looking for Abarelix API 183552-38-7?
- Description:
- Here you will find a list of producers, manufacturers and traders of Abarelix. You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Abarelix
- Synonyms:
- Cas Number:
- 183552-38-7
- DrugBank number:
- DB00106
- Unique Ingredient Identifier:
- W486SJ5824
About Abarelix
You can find a short description about Abarelix here. Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.
You can ask the supplier for more technical information about the product.
Abarelix is a type of Gonadorelin antagonists
Gonadorelin antagonists belong to a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that play a crucial role in the field of reproductive medicine. These antagonists specifically target and interact with gonadotropin-releasing hormone (GnRH) receptors in the body.
GnRH receptors are primarily located in the pituitary gland and are responsible for regulating the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). By inhibiting the binding of GnRH to its receptors, gonadorelin antagonists effectively block the signaling cascade that leads to the release of FSH and LH.
This mechanism of action has significant implications in reproductive medicine. Gonadorelin antagonists are commonly used in assisted reproductive technologies (ART) such as in vitro fertilization (IVF). By suppressing the endogenous secretion of FSH and LH, these antagonists prevent premature ovulation in women undergoing controlled ovarian stimulation. This allows for a more controlled and precise approach in ART procedures.
Moreover, gonadorelin antagonists are utilized in the treatment of certain hormone-dependent conditions, including prostate cancer and endometriosis. In prostate cancer, these antagonists can inhibit the production of testosterone, which fuels the growth of cancer cells. In endometriosis, they suppress the hormonal stimulation of abnormal endometrial tissue growth.
In summary, gonadorelin antagonists are a vital subclass of pharmaceutical APIs that selectively block GnRH receptors, influencing the regulation of reproductive hormones. Their applications range from controlled ovarian stimulation in ART to the management of hormone-dependent conditions like prostate cancer and endometriosis.
Abarelix (Gonadorelin antagonists), classified under Hormonal Agents
Hormonal agents are a prominent category of pharmaceutical active pharmaceutical ingredients (APIs) widely used in the medical field. These substances play a crucial role in regulating and modulating hormonal functions within the body. Hormonal agents are designed to mimic or manipulate the effects of naturally occurring hormones, allowing healthcare professionals to treat various endocrine disorders and hormonal imbalances.
Hormonal agents are commonly employed in the treatment of conditions such as hypothyroidism, hyperthyroidism, diabetes, and hormonal cancers. These APIs work by interacting with specific hormone receptors, either by stimulating or inhibiting their activity, to restore the balance of hormones in the body. They can be administered orally, intravenously, or through other routes depending on the specific medication and patient needs.
Pharmaceutical companies employ rigorous manufacturing processes and quality control measures to ensure the purity, potency, and safety of hormonal agent APIs. These APIs are synthesized using chemical or biotechnological methods, often starting from natural hormone sources or through recombinant DNA technology. Stringent regulatory guidelines are in place to guarantee the efficacy and safety of hormonal agent APIs, ensuring that patients receive high-quality medications.
As the demand for hormone-related therapies continues to grow, ongoing research and development efforts focus on enhancing the effectiveness and reducing the side effects of hormonal agent APIs. This includes the exploration of novel delivery systems, advanced formulations, and targeted drug delivery methods. By continuously advancing our understanding and capabilities in hormonal agents, the medical community can improve patient outcomes and quality of life for individuals with hormonal disorders.
